Seneca Therapeutics Announces the Dosing of the First Patient in the SVV-001 Phase I/II Trial
Trial to Demonstrate Safety and Preliminary Efficacy with Poorly Differentiated Neuroendocrine Carcinomas or High-Grade (Grade 3) Neuroendocrine Tumors PHILADELPHIA, PA, UNITED STATES, May 27, 2025 /EINPresswire.com/ -- Seneca Therapeutics announced …